129 related articles for article (PubMed ID: 10810957)
21. Estrogen replacement therapy and menopause.
Odom MJ; Carr BR
Compr Ther; 1987 Dec; 13(12):58-63. PubMed ID: 3440374
[No Abstract] [Full Text] [Related]
22. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
23. Vulvovaginal atrophy: new and upcoming approaches.
Simon JA
Menopause; 2009; 16(1):5-7. PubMed ID: 19131842
[No Abstract] [Full Text] [Related]
24. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension.
Vilodre LC; Osório Wender MC; Sisson de Castro JA; dos Reis FM; Ruschel S; Magalhães JA; Spritzer PM
Gynecol Endocrinol; 2003 Aug; 17(4):323-8. PubMed ID: 14503977
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.
Dessole S; Rubattu G; Ambrosini G; Gallo O; Capobianco G; Cherchi PL; Marci R; Cosmi E
Menopause; 2004; 11(1):49-56. PubMed ID: 14716182
[TBL] [Abstract][Full Text] [Related]
26. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
27. The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial.
Manonai J; Songchitsomboon S; Chanda K; Hong JH; Komindr S
Maturitas; 2006 May; 54(2):135-40. PubMed ID: 16297576
[TBL] [Abstract][Full Text] [Related]
28. The clinical platform for the 17beta-estradiol vaginal releasing ring.
Bachmann GA
Am J Obstet Gynecol; 1998 May; 178(5):S257-60. PubMed ID: 9609602
[TBL] [Abstract][Full Text] [Related]
29. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
Johansen OE; Qvigstad E
Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
[TBL] [Abstract][Full Text] [Related]
30. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women.
Naunton M; Al Hadithy AF; Brouwers JR; Archer DF
Menopause; 2006; 13(3):517-27. PubMed ID: 16735950
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee.
Cardozo L; Bachmann G; McClish D; Fonda D; Birgerson L
Obstet Gynecol; 1998 Oct; 92(4 Pt 2):722-7. PubMed ID: 9764689
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
Bachmann G; Lobo RA; Gut R; Nachtigall L; Notelovitz M
Obstet Gynecol; 2008 Jan; 111(1):67-76. PubMed ID: 18165394
[TBL] [Abstract][Full Text] [Related]
33. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review.
Sarkar NN
Eur J Contracept Reprod Health Care; 2003 Dec; 8(4):217-24. PubMed ID: 15006269
[TBL] [Abstract][Full Text] [Related]
34. Web-based survey on the effect of digital storytelling on empowering women to seek help for urogenital atrophy.
Cumming GP; Currie HD; Moncur R; Lee AJ
Menopause Int; 2010 Jun; 16(2):51-5. PubMed ID: 20729493
[TBL] [Abstract][Full Text] [Related]
35. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
36. Urogenital atrophy.
Pitkin J; Rees M;
Menopause Int; 2008 Sep; 14(3):136-7. PubMed ID: 18714081
[TBL] [Abstract][Full Text] [Related]
37. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
Crandall C
J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
[TBL] [Abstract][Full Text] [Related]
38. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
[TBL] [Abstract][Full Text] [Related]
39. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer.
Dew JE; Wren BG; Eden JA
Climacteric; 2003 Mar; 6(1):45-52. PubMed ID: 12725664
[TBL] [Abstract][Full Text] [Related]
40. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears.
Bateson DJ; Weisberg E
Menopause; 2009; 16(4):765-9. PubMed ID: 19407678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
